Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Retained Earnings (2020 - 2026)

Cardiol Therapeutics filings provide 3 years of Retained Earnings readings, the most recent being -$84.3 million for Q4 2022.

  • On a quarterly basis, Retained Earnings fell 27.25% to -$84.3 million in Q4 2022 year-over-year; TTM through Dec 2022 was -$84.3 million, a 27.25% decrease, with the full-year FY2022 number at -$84.3 million, down 27.25% from a year prior.
  • Retained Earnings hit -$84.3 million in Q4 2022 for Cardiol Therapeutics, down from -$82.0 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$39.8 million in Q4 2020 to a low of -$84.3 million in Q4 2022.
  • Median Retained Earnings over the past 3 years was -$69.6 million (2021), compared with a mean of -$67.4 million.
  • Biggest five-year swings in Retained Earnings: crashed 66.5% in 2021 and later fell 27.25% in 2022.
  • Cardiol Therapeutics' Retained Earnings stood at -$39.8 million in 2020, then crashed by 66.5% to -$66.3 million in 2021, then fell by 27.25% to -$84.3 million in 2022.
  • The last three reported values for Retained Earnings were -$84.3 million (Q4 2022), -$82.0 million (Q3 2022), and -$77.6 million (Q2 2022) per Business Quant data.